Skip to main content

Table 3 Primary analysis, baseline covariates after matching, stratified by age

From: Testosterone replacement therapy and the risk of adverse cardiovascular outcomes and mortality

Matching Variable

Age < 65 years

N = 304

Age ≥ 65 years

N = 71

P-value

Standardized

Mean

Difference

TRTa (N, %)

132 (43.4%)

33 (46.5%)

0.738

0.061

Median First Testosterone, ng/dL (IQR)

175 (145, 202)

185 (161, 196)

0.291

0.126

Median Second Testosterone, ng/dL (IQR)

169 (139, 195)

176 (141, 195)

0.526

0.040

Median Income, United States Dollars (IQR)

54,440 (44,810, 71,425)

61,069 (45,653, 66,588)

0.538

0.071

Median Age, years (IQR)

54 (48, 59)

69 (66, 74)

< 0.001

0.687

Diabetes (N, %)

116 (38.2%)

39 (54.9%)

0.014

0.341

Tobacco Use (N, %)

2 (0.1%)

0

1

0.115

LDL > 130 mg/dL

37 (12.2%)

1 (1.4%)

0.013

0.438

Median LDL, mg/dL (IQR)

95 (74, 117)

79 (59, 107)

0.001

0.536

Hypertension (N, %)

193 (63.5%)

60 (84.5%)

0.001

0.494

Statin (N, %)

147 (48.4%)

45 (63.4%)

0.032

0.306

BMI ≥ 30 kg/m2

276 (90.8%)

60 (84.5%)

0.179

0.192

Median BMI, kg/m2(IQR)

36.3 (32.2, 41.0)

34.1 (31.1, 37.9)

0.004

0.323

Previous Cardiovascular Disease (N, %)

35 (11.5%)

34 (47.9%)

< 0.001

0.868

Charlson Comorbidity Index (N, %)

  

< 0.001

1.068

0

134 (44.1%)

13 (18.3%)

  

1

85 (28.0%)

5 (7.0%)

  

> 1

85 (28.0%)

53 (74.6%)

  

Composite Outcome (N, %)

15 (4.9%)

13 (18.3%)

  

Myocardial Infarction (N, %)

5 (1.6%)

2 (2.8%)

  

Stroke (N, %)

8 (2.6%)

8 (11.3%)

  

Death (N, %)

2 (0.7%)

3 (4.2%)

  
  1. aTRT: Testosterone Replacement Therapy
  2. IQR: Interquartile range
  3. LDL: Low-density lipoproteins
  4. BMI: Body mass index
  5. Patients were matched by age, median income, diabetes, tobacco, hypertension, LDL, stain, aspirin, body mass index (BMI), previous cardiovascular disease (previous acute myocardial infarction or acute cerebrovascular accident, or cerebrovascular or cardiovascular disease), and Charlson Comorbidity Index. Median matched exposure time was 1 month (IQR: 0, 4), max 78 months
  6. A patient treated with TRT with X months of exposure time between baseline and the initiation of treatment was matched to a comparison group patient (no TRT) that had more than X months of follow up since baseline. This period of time (X months) is the matched exposure time